Close Menu

NEW YORK – Australian rapid diagnostic device firm Atomo Diagnostics announced Wednesday an agreement with Access Bio to commercialize two rapid COVID-19 antibody tests.

Atomo will supply its rapid diagnostic test devices to Access Bio for use with Access' rapid test strip to detect COVID-19 antibodies. After the necessary regulatory approvals have been obtained, a test for professional use and a self-test, cobranded by the two companies, will be launched in the US, Canada, and Mexico, they said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.